Engineering Summit in Lisbon
Due to a diary issue, ProfG is in clinic today and therefore Prof. Baker will be giving the lecture.
Overview on the Current Antibody Treatment of Multiple
Sclerosis Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath,Professor, Neurology, Centre for Neuroscience and Trauma, Barts and the London School of Medicine and Dentistry
Multiple sclerosis is a putative autoimmune disease of the central nervous system that is characterised pathologically by inflammation, demyelination and variable degrees of axonal loss. Numerous immunomodulatory therapies have been licensed, or are in late stage development, to treat multiple sclerosis including several monoclonal antibodies. Dissecting out the mode of action of the targeted monoclonal antibodies is providing interesting insights into the pathogenesis of MS.